The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Open accessAbstract
Chromosomal rearrangements have a central role in the pathogenesis of human cancers and often result in the expression of therapeutically actionable gene fusions. A recently discovered example is a fusion between the genes echinoderm microtubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an inversion on the short arm of chromosome 2: inv(2)(p21p23). The EML4-ALK oncogene is detected in a subset of human non-small cell lung cancers (NSCLC) and is clinically relevant because it confers sensitivity to ALK inhibitors. Despite their importance, modelling such genetic events in mice has proven challenging and requires complex manipulation of the germ line. Here we describe an efficient method to induce specific chromosomal rearrangements in vivo using viral-mediated delivery of the CRISPR/Cas9 system to somatic cells of adult animals. We apply it to generate a mouse model of Eml4-Alk-driven lung cancer. The resulting tumours invariably harbour the Eml4-Alk inversion, express the Eml4-Alk fusion gene, display histopathological and molecular features typical of ALK(+) human NSCLCs, and respond to treatment with ALK inhibitors. The general strategy described here substantially expands our ability to model human cancers in mice and potentially in other organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these events occur at low frequency, they could be significant in a clinical setting if rare translocations led to cancer 97-99 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [98]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, CRISPR/Cas9 system has shown potentials in polygenetic diseases, such as cancer, by inhibiting oncogene expression or deactivating oncogenic virus [52–55].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [55]
In the citing paper
“To establish disease models, in 2014, Maddalo et al. generated a model of non-small cell lung cancer by creating an Eml4 and Alk fusion gene through the intratracheal instillation of AdV-delivered CRISPR/Cas9 [35].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2291 · Cited by 896
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 873
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 633
Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations
Kalyanaraman, K. J., Corey, Z., Navarro, A., Heasley, L. E., & Nemenoff, R. A. (2025) · Cancers · doi:10.3390/cancers17152424 · Cited by 2
Zhang, D., Chiu, C.-L., Wen, R. M., Qiu, Z., Garcia-Marques, F. J., Bermudez, A., Zhao, M., Zhao, H., Dixon, S. J., Peehl, D. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113515 · Cited by 2
Shepard, A., Troutman, S. A., Hoxha, S., Lester, D., Khaled, W. T., Smith, E. S. J., Park, T. J., Buffenstein, R., Du, D., Teng, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0526 · Cited by 2
Self-citationLiu, B., Stuart, W. D., Fink-Baldauf, I. M., Boscolo, E., Mino-Kenudson, M. A., Snyder, E. L., & Maeda, Y. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c04269 · Cited by 2
The applications and advances of CRISPR-Cas9 in medical research
Lu, X., Sun, H., Xu, Y. J., Xi, Y., & Gu, B. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw036 · Cited by 2
CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy
Jacob, E. M., Borah, A., & Kumar, D. S. (2022) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-12658-1_2 · Cited by 3
Genome editing pig models with elements for controllable gene expression
Jin, Q., Shi, H., Liu, X., Ju, J., Wang, K., & Lai, L. (2023) · Animal Research and One Health · doi:10.1002/aro2.20 · Cited by 2
Genetic modification of mice using CRISPR-Cas9: Best practices and practical concepts explained
Hosur, V., Low, B. E., & Wiles, M. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-817218-6.00018-8 · Cited by 3
Primary lung adenocarcinoma with breast metastasis harboring the EML4‑ALK fusion: A case report
Zhang, W., Zhang, Y., Zhou, L., Tan, N., Bai, Y., & Xing, S. (2024) · Oncology Letters · doi:10.3892/ol.2024.14409 · Cited by 2
Peng, Y., Tsuno, Y., Maejima, T., Wang, M., Jung, J., Matsui, A., & Mieda, M. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003706 · Cited by 2
Modeling Cancer Using CRISPR-Cas9 Technology
Rodríguez, S., Martínez-Lage, M., & Torres-Ruiz, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00034-6 · Cited by 2
CRISPR-Cas9 in cancer therapeutics
Randhawa, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.016 · Cited by 2
Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas
Dawes, J., & Uren, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670280 · Cited by 2
Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors
Lomov, N. A., Viushkov, V. S., & Rubtsov, M. A. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923070040 · Cited by 2
Applications of CRSIPR/Cas9 in Cancer Research
Yue, J., Du, Z., Zhou, F. M., Dong, P., & Pfeffer, L. M. (2018) · Journal of Cancer Science and Research · doi:10.4172/2576-1447.1000103 · Cited by 2
Alladin, A., & Jechlinger, M. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.10.004 · Cited by 2
Kozhevnikova, E. N., Leshchenko, A. E., & Pindyurin, A. V. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918050115 · Cited by 2
Are there any good experiments that should not be done?
Pollack, R., & Cobb, M. A. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001539 · Cited by 2
The next generation personalized models to screen hidden layers of breast cancer tumorigenicity
Afzali, F., Akbari, P., Naderi‐Manesh, H., & Gardaneh, M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05159-2 · Cited by 2
INTRODUCING THE BRAVE NEW CRISPR WORLD
Gouw, A. M. (2020) · Zygon® · doi:10.1111/zygo.12594 · Cited by 2
PAZ domain is critical for spermatogenesis in chicken
Guo, Q., Lu, X., Yuan, X., Jiang, Y., Bai, H., & Chang, G. (2021) · Animal Biotechnology · doi:10.1080/10495398.2021.2011742 · Cited by 2
Studying Tumor Formation and Regulation in Xenopus
Tulkens, D., & Vleminckx, K. (2022) · CRC Press eBooks · doi:10.1201/9781003050230-24 · Cited by 2
The development of gene drives for genetic control of the malaria mosquito
Hammond, A. (2016) · Spiral (Imperial College London) · doi:10.25560/53131 · Cited by 2
Ng, W. A., & Reed, B. H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/815431 · Cited by 2
Hammad, M., Almahari, S. A., Umakanth, S., & Toorani, Z. A. (2024) · Cureus · doi:10.7759/cureus.67332 · Cited by 1
Molecular dependencies and genomic consequences of a global DNA damage tolerance defect
de Groot, D., Spanjaard, A., Shah, R., Kreft, M., Morris, B., Lieftink, C., Catsman, J. J. I., Ormel, S., Ayidah, M., Pilzecker, B., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03451-z · Cited by 1
Reyed, R. M., & Prabhakar, P. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36500-3.00008-8 · Cited by 1
Gutierrez, R., Chan, A. Y. S., Lai, S. W. T., Itoh, S., Lee, D.-H., Sun, K., Battad, A., Chen, S., O'Connor, T. R., & Shuck, S. C. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107492 · Cited by 1
Jasin, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-3509-3_1 · Cited by 3
Research progress on non-viral vectors of CRISPR/Cas9 system
Liu, Q., Zhang, Z., & Liu, Y. (2019) · Scientia Sinica Chimica · doi:10.1360/n032018-00233 · Cited by 1
The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions
Tabbò, F., Righi, L., Taulli, R., & Novello, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00010-3 · Cited by 1
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 1
CRISPR: A Promising Tool for Cancer Therapy
Mohammad‐Rafiei, F., Safdarian, E., Adel, B., Vandchali, N. R., Navashenaq, J. G., & Hayat, S. M. G. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220624111311 · Cited by 1
CRISPR/Cas-9 and its therapeutic applications in Onco-viral diseases
Naqvi, B. S. T., Alam, M., Nazir, A., Zeb, S., Khan, A., Malik, S. R., Shah, N., Naveed, M., & Khan, M. F. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.14029 · Cited by 1
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
DiMarco, A. V., Ravichandran, M., Lau, J., Lima, A., Lacap, J. A., Larrocha, P. S.-L., Lin, E., Weng, J., Gerosa, L., Hunsaker, T., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3662 · Cited by 1
Self-citationThe CRISPR road: from bench to bedside on an RNA-guided path.
García‐Bloj, B., Moses, C., & Blancafort, P. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.07.20 · Cited by 1
Sadhu, M. J., & Kruglyak, L. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0042 · Cited by 1
Ribonucleoproteins Mediated Efficient In Vivo Gene Editing in Skin Stem Cells
Wu, W., & Chen, T. (2018) · Methods in molecular biology · doi:10.1007/7651_2018_115 · Cited by 1
Delivery Methods for CRISPR/Cas Reagents
Ashraf, S., Munawar, N., Zahoor, M. K., Jamil, A., Hammad, M., Ghaffar, A., & Ahmad, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-6305-5_4 · Cited by 1
Genome characterization and CRISPR-Cas9 editing of a human neocentromere
Palazzo, A. J., Piccolo, I., Minervini, C. F., Purgato, S., Capozzi, O., D’Addabbo, P., Cumbo, C., Albano, F., Rocchi, M., & Catacchio, C. R. (2022) · Chromosoma · doi:10.1007/s00412-022-00779-y · Cited by 1
CRISPR e edição genômica: técnica, bioética e controvérsias
Nohama, N., Simão-Silva, D. P., Vaz, R. S., da Cunha, T. R., Fischer, M. L., Gomy, I., de Carvalho, K. A. T., Paes, A. L. F. D., Reynoso, F. A. W., Borgmann, A. V., et al. (2023) · doi:10.22533/at.ed.846232605 · Cited by 1
Tumour modelling using viral vectors
Frew, I. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4387 · Cited by 1
Excitation et crispations autour de CRISPR : lorsque la réalité dépasse la science-fiction
Kaplan, J. (2016) · Les Cahiers de Myologie · doi:10.1051/myolog/201613015 · Cited by 1
Precision Genome Editing for Systems Biology – A Temporal Perspective
Völlmy, F., & Linding, R. (2017) · Systems Biology · doi:10.1002/9783527696130.ch14 · Cited by 1
Pooled AAV-CRISPR Screen with Targeted Amplicon SequencingPreprint
Wang, G., Chow, R. D.-W., Ye, L., Guzman, C. D., Dai, X., Dong, M. B., Zhang, F., Sharp, P. A., Platt, R. J., & Chen, S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/153643 · Cited by 1
Modeling mixed-lineage-rearranged leukemia initiation in CD34 + cells: a “CRISPR” solution
Torres-Ruiz, R., Rodríguez, S., Bueno, C., & Menéndez, P. R. (2017) · Haematologica · doi:10.3324/haematol.2017.173740 · Cited by 1
Geng, K., Merino, L. G., Wedemann, L., Martens, A., Sobota, M., Sanchez, Y. P., Søndergaard, J. N., White, R. J., & Kutter, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.01.450727 · Cited by 1
Minimized combinatorial CRISPR screens identify genetic interactions in autophagy
Diehl, V. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.67332 · Cited by 1
Soltaninejad, H., Khoshandam, M., Hamidieh, A. A., & Hosseinkhani, S. (2022) · doi:10.22541/au.165268627.74823408/v1 · Cited by 1
Shahzaib, M., Brügmann, T., Shakeel, M., Khan, S. H., Azhar, M. T., Atif, R. M., Fladung, M., & Rana, I. A. (2023) · Preprints.org · doi:10.20944/preprints202305.1887.v1 · Cited by 1
Engineering Multiplexed Synthetic Breath Biomarkers as Diagnostic ProbesPreprint
Wang, S., Anahtar, M., Kim, D. M., Samad, T. S., Zheng, C. M., Patel, S., Ko, H., Ngambenjawong, C., Wang, C. S., Kirkpatrick, J. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.30.630769 · Cited by 1
Experimental demonstration of daisy chain gene drive and modelling of daisy suppression systemsPreprint
Guo, J., Chen, W., & Champer, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.20.677490 · Cited by 1
miRISC inhibition causes mitotic defects and synergizes with genotoxic agents in cancersPreprint
Zhang, M., Jiao, Z., Florez, Y. C., Lessel, I., Li, X., Yao, M. A., Weigl, M., Ozimek, M. M., Dogruluk, T., Chen, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693984 · Cited by 1
Self-citationComputational Biology-Driven Genomic and Epigenomic Delineation of Acute Myeloid Leukemia
Sanders, M. A. (2015) · EUR Research Repository (Erasmus University Rotterdam)
Animal Models of Human Pathology 2014
Fedele, M., Gualillo, O., & Vecchione, A. M. (2015) · BioMed Research International · doi:10.1155/2015/721348
Mechanism and engineering of CRISPR-associated endonucleases
Sternberg, S. H. (2014) · eScholarship (California Digital Library)
Congrès de l’association américaine de recherche contre le cancer — AACR 2016
Vicier, C., Guillebon, É. D., Kieffer, A., Turpin, A., Dumont, C., Bellesœur, A., Soares, D. G., & Lotz, J. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2647-z
Applications of CRISPR-Cas systems in neuroscience
Harvard, C. (2016)
CRISPR ‐Cas Systems for the Study of Immune Function
Pelletier, S. W. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0026896
[Use of a new peroral anticoryza drug. Experience in the industrial medical practice].
Schäfer, G. (1971) · PubMed
Das, M. (2017) · Brandeis Institutional Repository · doi:10.48617/etd.1019
Andrea Ventura: Decrypting noncoding RNAs
Casadio, M. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201705217
Dow, E. (2015)
Cell Reprogramming for Cardiac Regeneration and Rare Disease Modeling
Carvajal‐Vergara, X., Rodríguez-Madoz, J. R., Pelacho, B., & Prósper, F. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57153-9_9
Elucidation of Mechanisms of Fetal Hemoglobin Regulation by CRISPR/Cas9 Mediated Genome Editing
Canver, M. C. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
基于CRISPR/Cas9基因编辑技术的人类遗传疾病基因治疗相关研究进展
门, 可., 段, 醒., 杨, 阳., & 魏, 于. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00169
Genome Editing During Development Using the CRISPR-Cas Technology
Arzate‐Mejía, R. G., Licona-Limón, P., & Targa, F. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7714-7_16
Kuzmich, A. I., Zinovyeva, M. V., Potapov, V. K., Костина, М. Б., & Sverdlov, E. D. (2018) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416818010081
Howaidi, J., Howaidi, A., & Howaidi, F. (2019) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_52_18
Enhancing CRISPR deletion via pharmacological delay of DNA-PKPreprint
Bosch, N., Medová, M., Esposito, R., Pulido-Quetglas, C., Zimmer, Y., & Johnson, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.12.945907
Future technologies for preimplantation genetic applications
Kubikova, N., & Wells, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816561-4.00016-8
Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers
Floyd, W., Kuo, H.-C., Himes, J. E., Patel, R., & Kirsch, D. G. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_8
Development of CRISPR/Cas-mediated gene editing in the retina
Li, F. (2020) · UTAS Research Repository · doi:10.25959/23249972
Wang, N., Qi, X., Liu, C., Xie, C., & Zhu, J. (2020) · ACTA AGRONOMICA SINICA · doi:10.3724/sp.j.1006.2020.93064
Carmignotto, G. P. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.3.2019.tde-31052021-094248
The Development of Recombinant hSpCas9 Production System in E. coli
Uslu, M., Serasker, E., & Kocabaş, F. (2021) · Gene Editing · doi:10.29228/genediting.54955
Analyse von Krebsgenen: Schnelle Suche nach der „Nadel im Heuhaufen“
Lange, S., Saur, D., & Rad, R. (2016) · Deutsches Ärzteblatt · doi:10.3238/personko/2016.09.30.05
ElMallah, M. K., Kalfopolous, M., & Flotte, T. R. (2019) · Cancer · doi:10.1002/9781119645214.ch28
Utilizing CRISPR/Cas9 Technologies for in vivo Disease Modeling and Therapy
Badertscher, L., & Porritt, M. J. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch7
Phelps, M., & Chen, E. Y. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-30654-4_16
Faculty Opinions recommendation of Strategies for Efficient Genome Editing Using CRISPR-Cas9.
Ellis, R. E. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734555063.793559593
Kuzmich, A. I., Zinovyeva, M. V., Potapov, V. K., Костина, М. Б., & Sverdlov, E. D. (2018) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.18821/0208-0613-2018-36-1-3-8
New frontiers in CRISPR/Cas9 delivery systems delivery for gene editingPreprint
Khoshaman, K., Nasiri, M., Rezaee, M., Izadi, F., Mehrara, A., Sadeghi, L., Rezaeian, Y., Rezaei, E., Zarei, E., Rahmanian, S., et al. (2022) · doi:10.22541/au.165493454.42208986/v1
Brief Introduction to CRISPR Cas9
Nestor, M. W., & Wilson, R. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-98368-0_1
Brancato, V., Brentari, I., Tarrero, L. C., Furlan, M., Nicassio, F., & Denti, M. A. (2022) · Biology Open · doi:10.1242/bio.059597
Tholen, L. E., Schigt, H., Kleuskens, S., Bos, C., Spruijt, C. G., Willemsen, B. K., Vermeulen, M., Hoenderop, J. G. J., & de Baaij, J. H. F. (2022) · The FASEB Journal · doi:10.1096/fj.202201121r
Research Progress of Crispr / Cas9 System in Hematological Diseases and Cancer
Wu, J. (2022) · International Symposium on Artificial Intelligence for Medicine Sciences (ISAIMS) · doi:10.1145/3570773.3570830
Vanoli, F., & Antonescu, C. R. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23141
Ciampricotti, M., Karakousi, T. R., Richards, A. L., Quintanal-Villalonga, À., Karatza, A., Caeser, R., Costa, E. A., Allaj, V., Manoj, P., Spainhower, K. B., et al. (2023) · doi:10.1158/2159-8290.c.6549427.v1
Self-citationCiampricotti, M., Karakousi, T. R., Richards, A. L., Quintanal-Villalonga, À., Karatza, A., Caeser, R., Costa, E. A., Allaj, V., Manoj, P., Spainhower, K. B., et al. (2023) · doi:10.1158/2159-8290.c.6549427
Self-citationGhasemian, A., Nournia, E., Nikfar, G., Kohansal, M., Mohammad, G., Salahi, A., & Memariani, M. (2023) · Journal of Advanced Biomedical Sciences · doi:10.18502/jabs.v13i4.13897
Tang, K., Zhou, X., Fang, S., Vandenbulcke, E., Du, A., Shen, J., Cao, H., Zhou, J., Chen, K., Shan, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.585126
Mechanisms for the development of therapy-related leukaemia caused by topoisomerase inhibitors
Lomov, N. A., Viushkov, V. S., & Rubtsov, M. A. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523070047
FMO4 drives lung adenocarcinoma by stabilizing the MAT2A/MAT2B complex and hindering ferroptosisPreprint
Bracquemond, D., Mahdizadeh, S. J., Brunet, L., Thomas, Q. D., Bouclier, C., Colomb, M., Bourdel, S., Fabbrizio, E., Tourrière, H., Papon, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646284
BRAF V600E -Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingPreprint
Dacheux, M. A., Wu, M., Scherzer, M. T., Nillson, M., Murphy, B., Schuman, S. S., Ju, Z., Bivona, T. G., Lito, P., Gumbleton, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.04.652129
Advancement of CRISPR/Cas9 in Translational Biomedicines
Atale, N., Kong, Q., & Rani, V. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80973-6_5
La technologie CRISPR-Cas9 : une des clés des thérapies personnalisées ?
Larsen, C. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.02.006
Kaneko, S., Takasawa, K., Asada, K., Shiraishi, K., Ikawa, N., Machino, H., Shinkai, N., Matsuda, M., Masuda, M., Adachi, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26732491
Kaneko, S., Takasawa, K., Asada, K., Shiraishi, K., Ikawa, N., Machino, H., Shinkai, N., Matsuda, M., Masuda, M., Adachi, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26019718
Metadata
- Authors
- Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., Lowe, S. W., & Ventura, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Ospedaliera San Gerardo (IT)
- Corresponding author
- Ventura, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-10-22
- Volume
- 516
- Issue
- 7531
- Pages
- 423-427
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4270925
- OpenAlex
- W1972759536
- Cited by
- 640
- References
- 30
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 61 · 2021: 53 · 2020: 53 · 2019: 55 · 2018: 68 · 2017: 65 · 2016: 81 · 2015: 63 · 2014: 2
- FWCI
- 28.86
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-06-24)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, P01CA013106, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EML4-ALK fusion, chromosomal rearrangements, non-small cell lung cancer, somatic genome editing, tumor suppressor, oncogene cooperation
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Cells, Cultured, Disease Models, Animal, Genetic Engineering, Chromosome Inversion, Lung Neoplasms, Pyrazoles, Pyridines, Translocation, Genetic, Receptor Protein-Tyrosine Kinases, NIH 3T3 Cells, Protein Kinase Inhibitors, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
